Applications of simulation models

The table below is based on a systematic review: Hua X. Lung TWC, Palmer A, Si L., Herman WH, Clarke P. How consistent is the relationship between improved glucose control and modelled health outcomes for people with type 2 diabetes? A systematic review, March 2017, Volume 35, Issue 3, pp 319–329

 

The list reports studies involving interventions that had an impact on blood glucose for people with Type 2 diabetes. The review was completed on 1 June 2015. We would be  interested in receiving information about additional health economic applications of diabetes simulation models.

1. Afzali HHA, Gray J, Beilby J, et al. A model-based economic evaluation of improved primary care management of patients with type 2 diabetes in Australia. Applied health economics and health policy. 2013; 11: 661–70.

2. Gilmer TP, O'Connor PJ, Sperl-Hillen JM, et al. Cost-effectiveness of an electronic medical record based clinical decision support system. Health Serv Res. 2012; 47: 2137-58.

 

3. Gao L, Zhao FL, Li SC. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. Int J Technol Assess Health Care. 2012; 28: 436-44.

 

4. Gillespie P, O'Shea E, Paul G, et al. Cost effectiveness of peer support for type 2 diabetes. Int J Technol Assess Health Care. 2012; 28: 3-11.

 

5. Coyle D, Coyle K, Kenny GP, et al. Cost-effectiveness of exercise programs in type 2 diabetes. Int J Technol Assess Health Care. 2012; 28: 228-34.

 

6. Tunis SL. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin. Applied health economics and health policy. 2011; 9: 351–65.

 

7. Cameron C, Coyle D, Ur E, et al. Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin. Cmaj. 2010; 182: 28-34.

 

8. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technology Assessment. 2010; 14: 1-+.

 

9. Brown ST, Grima DG, Sauriol L. Cost-effectiveness of Insulin Glargine Versus Sitagliptin in Insulin-naïve Patients With Type 2 Diabetes Mellitus. Clinical therapeutics. 2014; 36: 1576-87.

 

10. Tzanetakos C, Melidonis A, Verras C, et al. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC health services research. 2014; 14: 419.

 

11. Shafie AA, Gupta V, Baabbad R, et al. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2014; 16: 926-38.

 

12. Giorda C, Nicolucci A, Pellegrini F, et al. Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi‐annals initiative: a long‐term cost‐effectiveness analysis. Diabetic Medicine. 2014; 31: 615-23.

 

13. Fonseca T, Clegg J, Caputo G, et al. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥ 30 kg/m2 in Spain. Journal of medical economics. 2013; 16: 926-38.

14.  Raya PM, Pérez A, de Arellano AR, et al. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Therapy. 2013; 4: 417-30.

 

15.  Pollock R, Muduma G, Valentine W. Evaluating the cost‐effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK. Diabetes, Obesity and Metabolism. 2013; 15: 121-29.

 

16. Davies M, Chubb B, Smith I, et al. Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in Type 2 diabetes mellitus. Diabetic Medicine. 2012; 29: 313-20.

 

17.  Guillermin A-L, Lloyd A, Best JH, et al. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. Journal of medical economics. 2012; 15: 654-63.

 

18.  Lee WC, Samyshkin Y, Langer J, et al. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. Journal of medical economics. 2012; 15: 28-37.

 

19.  Pollock RF, Curtis BH, Valentine WJ. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. Journal of medical economics. 2012; 15: 766-75.

20. Pollock RF, Curtis BH, Smith-Palmer J, et al. A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin. Advances in therapy. 2012; 29: 1051-66.

21. Samyshkin Y, Guillermin A-L, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. Journal of medical economics. 2012; 15: 6-13.

22. Smith-Palmer J, Fajardo-Montanana C, Pollock R, et al. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of medical economics. 2012; 15: 977-86.

23. Valov V, Palmer J, Czech M, et al. Cost-Effectiveness of Biphasic Insulin Aspart 30 VS. Human Premix Insulin in Type 2 Diabetes from the Payer's Perspective in Bulgaria. Biotechnology & Biotechnological Equipment. 2012; 26: 2937-44.

24.  Yang L, Christensen T, Sun F, et al. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study. Value Health. 2012; 15: S56-S59.

 

25.  Beaudet A, Palmer JL, Timlin L, et al. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK. J Med Econ. 2011; 14: 357-66.

26. Goodall G, Costi M, Timlin L, et al. Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinol Nutr. 2011; 58: 331-40.

27.  Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Curr Med Res Opin. 2011; 27: 897-906.

28. Valentine WJ, Palmer AJ, Lammert M, et al. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clinical therapeutics. 2011; 33: 1698-712.

29. Lee WC, Conner C, Hammer M. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clin Ther. 2010; 32: 1756-67.

30. Palmer JL, Beaudet A, White J, et al. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Adv Ther. 2010; 27: 814-27.

31.  Palmer JL, Knudsen MS, Aagren M, et al. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting. J Med Econ. 2010; 13: 212-20.

32. Pollock RF, Valentine WJ, Goodall G, et al. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents. Swiss medical weekly. 2010; 140: 36.

33. Tunis SL, Sauriol L, Minshall ME. Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada. Appl Health Econ Health Policy. 2010; 8: 267-80.

34.  Tunis SL, Willis WD, Foos V. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain. Curr Med Res Opin. 2010; 26: 163-75.

35.  Tunis SL, Minshall ME. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US. Curr Med Res Opin. 2010; 26: 151-62.

 

36. Tunis SL, Minshall ME, Conner C, et al. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis. Curr Med Res Opin. 2009; 25: 1273-84.

37.  Brandle M, Erny-Albrecht KM, Goodall G, et al. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. Int J Clin Pharmacol Ther. 2009; 47: 501-15.

38.  Brandle M, Goodall G, Erny-Albrecht KM, et al. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Med Wkly. 2009; 139: 173-84.

 

39.   Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. Cmaj. 2009; 180: 400-7.

 

40.  Goodall G, Sarpong EM, Hayes C, et al. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC endocrine disorders. 2009; 9: 19.

 

41.   Lee KH, Seo SJ, Smith‐Palmer J, et al. Cost‐Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea. Value in Health. 2009; 12: S55-S61.

 

42. Mittendorf T, Smith‐Palmer J, Timlin L, et al. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost‐effectiveness analysis in the German setting. Diabetes, Obesity and Metabolism. 2009; 11: 1068-79.

 

43. Scherbaum WA, Goodall G, Erny-Albrecht KM, et al. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost effectiveness and resource allocation : C/E. 2009; 7: 9.

44. Valentine WJ, Tucker D, Palmer AJ, et al. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive. Value Health. 2009; 12: 1-9.

 

45. St Charles M, Minshall ME, Pandya BJ, et al. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. Curr Med Res Opin. 2009; 25: 1343-53.

 

46.  Ali M, White J, Lee CH, et al. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. J Med Econ. 2008; 11: 651-70.

 

47.  Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, et al. Cost‐Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand. Value in Health. 2008; 11: S43-S51.

 

48. Goodall G, Jendle J, Valentine W, et al. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long‐term health economic implications in a Swedish setting. International journal of clinical practice. 2008; 62: 869-76.

 

49. Minshall ME, Oglesby AK, Wintle ME, et al. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health. 2008; 11: 22-33.

 

50. Palmer JL, Gibbs M, Scheijbeler HW, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Adv Ther. 2008; 25: 752-74.

 

51.  Palmer JL, Goodall G, Nielsen S, et al. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Curr Med Res Opin. 2008; 24: 1417-28.

 

52. Valentine WJ, Goodall G, Aagren M, et al. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Adv Ther. 2008; 25: 567-84.

 

53. Tunis SL, Minshall ME. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states. Am J Manag Care. 2008; 14: 131-40.

 

54. Tunis SL, Minshall ME, St CM, et al. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. Curr Med Res Opin. 2008; 24: 3085-96.

 

55. Gilmer TP, Roze S, Valentine WJ, et al. Cost-effectiveness of diabetes case management for low-income populations. Health Serv Res. 2007; 42: 1943-59.

 

56.  Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin. 2007; 23: 609-22.

 

57. Ray J, Valentine W, Roze S, et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost‐effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US*. Diabetes, Obesity and Metabolism. 2007; 9: 103-13.

 

58. Valentine WJ, Erny-Albrecht KM, Ray JA, et al. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Adv Ther. 2007; 24: 273-90.

59. Valentine WJ, Bottomley JM, Palmer AJ, et al. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med. 2007; 24: 982-1002.

 

60. Palmer AJ, Dinneen S, Gavin JR, et al. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin. 2006; 22: 861-72.

 

61. Roze S, Valentine WJ, Evers T, et al. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. Curr Med Res Opin. 2006; 22: 1415-24.

 

62. Valentine W, Palmer A, Nicklasson L, et al. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. International journal of clinical practice. 2006; 60: 1138-45.

 

63. Valentine WJ, Palmer AJ, Lammert M, et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin. 2005; 21: 2063-71.

 

64. Palmer AJ, Roze S, Lammert M, et al. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Current Medical Research and Opinion®. 2004; 20: S41-S51.

 

65. Palmer AJ, Roze S, Valentine WJ, et al. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Current Medical Research & Opinion. 2004; 20 Suppl 1: S53-8.

 

66. Van Haalen HGM, Pompen M, Bergenheim K, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clinical Drug Investigation. 2014; 34: 135-46.

 

67. Elgart JF, Caporale JE, Gonzalez L, et al. Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Economics Review. 2013; 3: 11.

 

68. Grzeszczak W, Czupryniak L, Kolasa K, et al. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technology & Therapeutics. 2012; 14: 65-73.

 

69. Granstrom O, Bergenheim K, McEwan P, et al. Cost-effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary care diabetes. 2012; 6: 127-36.

 

70.  Erhardt W, Bergenheim K, Duprat-Lomon I, et al. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clinical Drug Investigation. 2012; 32: 189-202.

 

71. Neslusan C, Teschemaker A, Johansen P, et al. Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value in Health Regional Issues. 2015; 8: 8-19.

 

72. Gillett M, Dallosso HM, Dixon S, et al. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. BMJ. 2010; 341: c4093.

 

73. Ryabov I. Cost-effectiveness of Community Health Workers in controlling diabetes epidemic on the U.S.-Mexico border. Public Health. 2014; 128: 636-42.

 

74. Hoerger TJ, Zhang P, Segel JE, et al. Improvements in risk factor control among persons with diabetes in the United States: Evidence and implications for remaining life expectancy. Diabetes Research and Clinical Practice. 2009; 86: 225-32.

 

75. Brownson CA, Hoerger TJ, Fisher EB, et al. Cost-effectiveness of diabetes self-management programs in community primary care settings. Diabetes Educator. 2009; 35: 761-9.

 

76. Group CDCDC-e. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002; 287: 2542-51.